• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Gilead Illinois





















how did we lose our home state of IL Medicaid to Gilead? Mav getting denied. Also heard CA has exclusive contracts for Medicaid. Wtf


Uh, Express scripts told y’all in August 2018, you’re off formulary. Gileads Epclusa, Harvoni and Vosevi along with Merck’s Zepatier are preferred therapies.Abbvies benefit managers are horrible. Old news if you’re referring in Expess.
 




Let’s face it, providers don’t like Mav and you thought low balling the price would lock out Gilead long term. They called your bluff and now watch out. You put lipstick on a pig, Mav is still a pig